Trabectedin

CHEMBL450449 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

761.8 g/mol

LogP

3.4

Phase

4

Trabectedin (ecteinascidin-743, ET-743) is a marine-derived tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA, distorting the DNA helix, stalling RNA polymerase II, and triggering nucleotide excision repair machinery to generate lethal double-strand breaks preferentially in actively transcribed genes. It is approved for unresectable soft tissue sarcoma and relapsed ovarian cancer (in combination with pegylated liposomal doxorubicin), and is under investigation for other malignancies. Its unique mechanism of action in transcription-coupled repair makes it active in tumors with deficient homologous recombination.

Molecular Weight

761.8000 g/mol

LogP

3.40

TPSA

194.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Leukemia Lymphoma Ovarian Cancer Pancreatic Cancer Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4

InChI

InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1

Molecular Formula

C39H43N3O11S

HBD / HBA

4 / 15

Rotatable Bonds

4

Heavy Atoms

54

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Trabectedin (ecteinascidin-743, ET-743) is a marine-derived tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA, distorting the DNA helix, stalling RNA polymerase II, and triggering nucleotide excision repair machinery to generate lethal double-strand breaks preferentially in actively transcribed genes. It is approved for unresectable soft tissue sarcoma and relapsed ovarian cancer (in combination with pegylated liposomal doxorubicin), and is under investigation for other malignancies. Its unique mechanism of action in transcription-coupled repair makes it active in tumors with deficient …

Yes, Trabectedin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL450449. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 108150. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Trabectedin on PillFYI

Structure

Quick Data

Formula: C39H43N3O11S
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.